What Is Your Differential Diagnosis?
Despite the possible explanation of (multi-) drug resistant TB, the continued weight loss and the appearance of new lesions warranted a revision of the initial diagnosis and additional investigations. In this woman, the differential diagnoses included but were not limited to TB of the skin, Kaposi sarcoma, atypical mycobacteria infection, disseminated fungal diseases, and neoplastic mimics of Kaposi sarcoma-like cutaneous T cell lymphoma. The situation was complicated by the fact that the patient had a high HIV-1 viral load at the beginning of TB treatment, and restarting her antiviral treatment together with her TB treatment could have led to clinical deterioration because of immune reconstitution inflammatory syndrome occurrence.
What Investigations Would You Ask For?
In our resource-limited setting, we opted for a stepwise approach. A chest X-ray was unremarkable (not shown); the serum antigen test for Cryptococcus neoformans was negative. A skin biopsy showed Histoplasmosis capsulatum infection. We did not have access to H. capsulatum detection tests. For a review of molecular epidemiology, clinical findings, diagnosis, and treatment of histoplasmosis in HIV-infected patients, please refer to the review of Adenis [1] . The woman was hospitalized for treatment of disseminated histoplasmosis. Treatment for severe disseminated histoplasmosis ideally consists of liposomal amphotericin B 3 mg/kg/d for seven to 14 days or until clinical improvement, followed by itraconazole 200 mg three times daily for three days, then 200 mg twice daily for at least 12 months where available [2] . In our setting, only amphotericin B deoxycholate and fluconazole were available. We treated the patient with 0.7 mg/kg amphotericin B deoxycholate for 14 days, then switched to fluconazole 400 mg twice daily for two weeks and afterwards to 400 mg once daily for a maintenance phase.
Because of the initial clinical response to TB treatment, the TB treatment was continued. Based on the Ugandan national guidelines, and to avoid rifampicin-lopinavir/ritonavir interaction, we choose ethambutol/isoniazid for maintenance treatment, although this regime has been shown to be inferior to rifampicin/isoniazid [3] .
Follow-up
The lesions responded very well to amphotericin B deoxycholate treatment, and the patient's weight began to increase (see Table 1 and Fig 1) . A follow-up abdominal ultrasound on 28th October 2013 showed that the lymphadenopathy had been resolved. During the amphotericin B deoxycholate therapy, we regularly monitored serum electrolytes and the GFR. The GFR remained stable over time. Four months into antifungal treatment, the patient reached her baseline body weight of 46 kg and the lesions had healed (see Fig 2B and 2C) .
The patient was seen regularly, and the fluconazole was stopped on 4th December 2014. She did not develop any new skin lesions and was last seen on 16th June 2015. On that day, her CD4 T cell count was 19 cells/microliter, and her HIV-1 RNA viral load was 252,000 copies/ milliliter. Her body weight was stable at 49 kg, and the patient did not have any clinical complaints. The patient is still on failing second-line antiretroviral treatment and has been enrolled in the control arm of the AIDS Clinical Trial Group Study A5288 (Management Using the Latest Technologies in Resource-Limited Settings to Optimize Combination Therapy After Viral Failure).
Case Discussion
This case illustrates the challenges of diagnosing (disseminated) histoplasmosis in our particular setting. Without skin involvement, the diagnosis would have been difficult to ascertain, as H. capsulatum serum antigen tests were not available. The overlap of histoplasmosis and TB clinical findings is shown in Table 2 .
Data on drug-resistant, extrapulmonary TB in Uganda is only anecdotal, but the first national survey published in 2013 showed that the 1.4% of previously untreated sputum Table 2 . Common clinical symptoms of disseminated histoplasmosis and tuberculosis. smear-positive TB patients were multidrug-resistant [4] . Because the patient was critically ill and response to TB treatment can take several weeks or even months, we decided to continue TB treatment. In view of the response to the antifungal treatment, continuation of TB treatment should be seen as critical in retrospect.
Because of financial constraints, state-of-the-art maintenance treatment with itraconazole could not be provided. In addition, use of itraconazole warrants pharmacological monitoring, which was not available in our setting. Nevertheless, the patient responded well to fluconazole.
